Quantitative assessment of cardiovascular autonomic impairment in cancer survivors: a single center case series
Tóm tắt
Cardiovascular autonomic dysfunction in cancer survivors is poorly understood. To better characterize the clinical characteristics and types of autonomic dysfunction in this population. A retrospective analysis of cancer survivors within an academic cardio-oncology program referred for suspected autonomic dysfunction was performed. Autonomic reflex testing of adrenergic, cardiovagal, and sudomotor function was done. Autonomic impairment was graded on severity based on the Composite Autonomic Severity Score system. Patients with pre-existing autonomic dysfunction prior to their cancer diagnosis were excluded. Of approximately 282 total patients in the UCLA Cardio-Oncology program, 24 were referred for suspected autonomic dysfunction and met the inclusion criteria. 22 had autonomic impairment on autonomic reflex testing. Eight patients were female, and the mean age at time of autonomic testing was 51.3 years. The average duration from cancer diagnosis to autonomic testing was 10.3 years. The reasons for referral included dizziness, tachycardia, palpitations, and syncope. The majority of patients (75%) had hematologic disorders. The most common chemotherapies administered were vinca alkaloids (54.2%), alkylating agents (66.7%), and anthracyclines (54.2%). Most patients received radiation to the thorax (66.7%) and neck (53.3%). Eleven patients had mild autonomic impairment, 7 had moderate, and 4 had severe autonomic impairment. Dysfunction was commonly present in the sympathetic and parasympathetic branches, but most pronounced in the sympathetic system. The majority of patients were diagnosed with orthostatic hypotension (50%), inappropriate sinus tachycardia (20.8%), and postural orthostatic tachycardia syndrome (12.5%) and had subjective improvement with treatment. Cardiovascular autonomic dysfunction occurs in cancer survivors, and commonly affects both the sympathetic and parasympathetic systems. Symptom recognition in patients should prompt autonomic testing and treatment where appropriate.
Tài liệu tham khảo
Society AC. Cancer facts & figures 2019, vol. 2019; 2019.
Society AC. Cancer treatment & survivorship facts & figures 2019–2021. Atlanta: American Cancer Society; 2019.
Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press; 2005.
Lakoski SG, Jones LW, Krone RJ, Stein PK, Scott JM. Autonomic dysfunction in early breast cancer: incidence, clinical importance, and underlying mechanisms. Am Heart J. 2015;170(2):231–41.
Coumbe BGT, Groarke JD. Cardiovascular autonomic dysfunction in patients with cancer. Curr Cardiol Rep. 2018;20(8):69.
Stone CA, Kenny RA, Nolan B, Lawlor PG. Autonomic dysfunction in patients with advanced cancer; prevalence, clinical correlates and challenges in assessment. BMC Palliat Care. 2012;11(1):3.
Guo Y, Palmer JL, Strasser F, Yusuf SW, Bruera E. Heart rate variability as a measure of autonomic dysfunction in men with advanced cancer. Eur J Cancer Care. 2013;22(5):612–6.
Bruera E, Chadwick S, Fox R, Hanson J, MacDonald N. Study of cardiovascular autonomic insufficiency in advanced cancer patients. Cancer Treat Rep. 1986;70(12):1383–7.
Walsh D, Nelson KA. Autonomic nervous system dysfunction in advanced cancer. Support Care Cancer. 2002;10(7):523–8.
Turner ML, Boland OM, Parker AC, Ewing DJ. Subclinical autonomic dysfunction in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol. 1993;84(4):623–6.
Bilora F, Veronese F, Zancan A, Biasiolo M, Pomerri F, Muzzio PC. Autonomic dysfunction in Hodgkin and non-Hodgkin lymphoma. A paraneoplastic syndrome? Hematol Rep. 2010;2(1):e8.
Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139–48.
Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, et al. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol. 2015;65(6):573–83.
Adams SC, Schondorf R, Benoit J, Kilgour RD. Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study. BMC Cancer. 2015;15:414.
Novak P. Quantitative autonomic testing. J Vis Exp. 2011;(53):e2502. https://doi.org/10.3791/2502.
Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson disease. In: Handbook of clinical neurology, vol. 117. Amsterdam: Elsevier; 2013. p. 259–78.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553–79.
Goldstein DS, Holmes C, Li S-T, Bruce S, Metman LV, Cannon RO III. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med. 2000;133(5):338–47.
Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li S-T. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease. Neurology. 2002;58(8):1247–55.
Low PA, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O’Brien PC, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care. 2004;27(12):2942–7.
Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc. 1993;68(8):748–52.
Kimpinski K, Iodice V, Burton DD, Camilleri M, Mullan BP, Lipp A, et al. The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophy. J Neurol Sci. 2012;317(1):92–6.
Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975–2015. Bethesda: National Cancer Institute; 2018.
Deuring G, Kiss A, Halter J, Passweg J, Grossman P. Cardiac autonomic functioning is impaired among allogeneic hematopoietic stem cell transplantation survivors: a controlled study. Bone Marrow Transplant. 2017;52(1):66–72.
Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9–17.
Roca E, Bruera E, Politi PM, Barugel M, Cedaro L, Carraro S, et al. Vinca alkaloid-induced cardiovascular autonomic neuropathy. Cancer Treat Rep. 1985;69(2):149–51.
Dobrek L, Baranowska A, Thor PJ. The influence of oxazaphosphorines alkylating agents on autonomic nervous system activity in rat experimental cystitis model. Acta Pol Pharm. 2013;70(6):1097–105.
Tjeerdsma G, Meinardi MT, van Der Graaf WT, van Den Berg MP, Mulder NH, Crijns HJ, et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999;81(4):419–23.
Sacre JW, Franjic B, Jellis CL, Jenkins C, Coombes JS, Marwick TH. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging. 2010;3(12):1207–15.
Sheldon RS, Grubb BP, Olshansky B, Shen W-K, Calkins H, Brignole M, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41–63.
Cuomo JR, Sharma GK, Conger PD, Weintraub NL. Novel concepts in radiation-induced cardiovascular disease. World J Cardiol. 2016;8(9):504–19.
Eschlböck S, Wenning G, Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm. 2017;124(12):1567–605.